Domenico Raimondo

– Therapeutic Targets in Multiple Myeloma: CD38–cGAMP and Gadd45β–MKK7 Interactions

Using computational modeling integrated with experimental data, I contributed to characterizing CD38 as a direct binder and inhibitor of extracellular cGAMP, revealing a novel immunoregulatory function. I also supported the design of D-peptides targeting the Gadd45β–MKK7 interaction to induce apoptosis in multiple myeloma cells, uncovering new therapeutic strategies.

– Computational Investigation of Chemerin–CCRL2 Recognition and Antibody-Related Projects

I employ advanced molecular dynamics simulations to study receptor–ligand interactions, particularly in immune-related targets. My research on the CCRL2–Chemerin complex, using a multiscale computational strategy that combines coarse-grained and all-atom MD simulations, provided mechanistic insights into ligand recognition and binding. I am also involved in projects related to antibodies and immune-mediated pathologies.

– Structural Modeling of hNOX2 for Drug Discovery

I contributed to developing a dynamic structural model of hNOX2, a key enzyme in ROS production, using advanced simulations of membrane protein complexes and molecular docking experiments. This model is now being used as a platform for in silico screening of potential NOX2 inhibitors.

– Pin1–Notch3 Interaction in Ovarian Cancer Chemoresistance

Using molecular dynamics approch and advanced structural bioinformatics tools, I analyzed the Pin1–Notch3 interface and identified a motif on Notch3 essential for stable binding. These findings provide molecular insights into platinum resistance in high-grade serous ovarian cancer and may support targeted therapy development.